Activity of the pan-class I phosphoinositide 3-kinase inhibitor NVP-BKM120 in T-cell acute lymphoblastic leukemia.
about
Deconvolution of Buparlisib's mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention.Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia.Targeting phosphatidylinositol-3-kinase pathway for the treatment of Philadelphia-negative myeloproliferative neoplasms.PI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors.Aquaporin 5 Plays a Role in Estrogen-Induced Ectopic Implantation of Endometrial Stromal Cells in EndometriosisLncRNA NALT interaction with NOTCH1 promoted cell proliferation in pediatric T cell acute lymphoblastic leukemia.Targeting mTOR signaling pathways and related negative feedback loops for the treatment of acute myeloid leukemia.Targeting IRAK1 in T-cell acute lymphoblastic leukemiaThe pan-class I phosphatidyl-inositol-3 kinase inhibitor NVP-BKM120 demonstrates anti-leukemic activity in acute myeloid leukemia.Effects of PI3K inhibitor NVP-BKM120 on overcoming drug resistance and eliminating cancer stem cells in human breast cancer cellsOpposing actions of angiopoietin-2 on Tie2 signaling and FOXO1 activationImproving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway.New Approaches to Target T-ALL.Outlook on PI3K/AKT/mTOR inhibition in acute leukemia.Emerging immunological drugs for chronic lymphocytic leukemia.Nuclear Localization of Diacylglycerol Kinase Alpha in K562 Cells Is Involved in Cell Cycle Progression.Identification of differential PI3K pathway target dependencies in T-cell acute lymphoblastic leukemia through a large cancer cell panel screen.Therapeutic targeting of IL-7Rα signaling pathways in ALL treatment.CHK1 overexpression in T-cell acute lymphoblastic leukemia is essential for proliferation and survival by preventing excessive replication stress.Aberrant Signaling Pathways in T-Cell Acute Lymphoblastic Leukemia.Activity of BKM120 and BEZ235 against Lymphoma Cells.Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia.Distinct oncogenic Ras signals characterized by profound differences in flux through the RasGDP/RasGTP cycleTriple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia.Targeting signaling and apoptotic pathways involved in chemotherapeutic drug-resistance of hematopoietic cells.Pan-class I PI3-kinase inhibitor BKM120 induces MEK1/2-dependent mitotic catastrophe in non-Hodgkin lymphoma leading to apoptosis or polyploidy determined by Bax/Bak and p53.Comprehensive analysis of T cell leukemia signals reveals heterogeneity in the PI3 kinase-Akt pathway and limitations of PI3 kinase inhibitors as monotherapy.
P2860
Q30841629-0E31B3C5-9FD4-4817-B416-C1D4EAE7D660Q33952803-0CA7C6EE-FFAE-4347-ADD1-1732E94EDE0AQ35727453-B329D6C8-7E9C-451A-9247-A925132B37C5Q35833018-3F483801-0DF5-4812-B9BC-5D60659F07D1Q35872133-9A65CAD9-ACA8-4A14-9A30-B85A2846844CQ36018337-2DC9B4A6-4118-44A5-B7C5-70F412641BA2Q36214081-7CFBA0CE-BDD5-4176-A80E-D6757F18D94FQ36326296-34096E1E-E292-4B16-B2DD-5C63E3FCF4E8Q36379644-AB58B408-000C-4D44-96F9-ABA76D30B2BEQ36485168-D6F954EB-CAB7-45EC-A5C0-D47F274CB0F5Q37217491-87A0AA2F-0553-4A1C-A238-833A231D4C82Q37360025-228B736F-AC93-4B9A-9861-55E007F87B41Q38234993-5294CC28-5BCA-4A9F-BC18-2A3917F2CC5AQ38521775-274645D6-1E8B-4706-B1D3-760EF68F9E1BQ38543771-F5A8A0AE-2C1E-4D8F-BCE7-9787239A261BQ38741590-96449A9F-1076-489B-A62F-C9D00300E48EQ38785283-8CD1D37A-3090-4E54-93D1-143C70DEBB3DQ38856941-9324B52E-1199-4097-896A-0D85A902B26EQ38965035-746B52F8-1D87-4401-9726-5E4FC129A971Q41660964-7E4CECA5-3422-41FE-83AB-DFD66FA1A0E7Q41855451-E3CA92C9-574C-4C3E-B458-80FDB33582BEQ41904096-92BC2A0B-A3FC-4E50-B33F-31FE0BF23B17Q42319027-C20127E6-AF90-4864-972B-7FF57A6BAEB6Q42440865-7992559B-5EDE-4B7F-9DB5-B7087B7A3CA8Q47110143-BACE40AC-2DBA-42A5-8A33-510D69A77CA9Q52363953-5BA3D882-9633-49DC-A0DC-EE078661F91EQ54978251-5AE85C2D-3945-43A8-99ED-B55B2230BCF5
P2860
Activity of the pan-class I phosphoinositide 3-kinase inhibitor NVP-BKM120 in T-cell acute lymphoblastic leukemia.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Activity of the pan-class I ph ...... acute lymphoblastic leukemia.
@en
Activity of the pan-class I ph ...... acute lymphoblastic leukemia.
@nl
type
label
Activity of the pan-class I ph ...... acute lymphoblastic leukemia.
@en
Activity of the pan-class I ph ...... acute lymphoblastic leukemia.
@nl
prefLabel
Activity of the pan-class I ph ...... acute lymphoblastic leukemia.
@en
Activity of the pan-class I ph ...... acute lymphoblastic leukemia.
@nl
P2093
P2860
P50
P356
P1433
P1476
Activity of the pan-class I ph ...... l acute lymphoblastic leukemia
@en
P2093
A Bertaina
A M Martelli
F Locatelli
F Melchionda
I L Antunes
P L Tazzari
P Pagliaro
P2860
P2888
P304
P356
10.1038/LEU.2013.369
P577
2013-11-06T00:00:00Z